Press releases
- Arrowhead Pharmaceuticals Reports Fiscal 2024 Second Quarter Results
- Arrowhead Pharmaceuticals Earns $50 Million Milestone from Royalty Pharma
- Arrowhead Pharmaceuticals to Participate in Upcoming May 2024 Conferences
- Arrowhead Pharmaceuticals to Host 2024 Summer Series of R&D Webinars
- Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Second Quarter Results
- Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease
- Arrowhead Pharmaceuticals Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo
- Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
- Arrowhead Pharmaceuticals Initiates Expanded Access Program for Plozasiran and Announces Upcoming Presentation of Clinical Data
- Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy
More ▼
Key statistics
On Friday, Arrowhead Pharmaceuticals Inc (A2RR34:SAO) closed at 15.63, 10.15% above the 52 week low of 14.19 set on May 10, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | 8.55 |
Offer | 17.50 |
Previous close | 15.63 |
Average volume | 33.33 |
---|---|
Shares outstanding | -- |
Free float | -- |
P/E (TTM) | -- |
Market cap | -- |
EPS (TTM) | -- |
Data delayed at least 15 minutes, as of May 18 2024 00:00 BST.
More ▼